
On 20 November 2026 Merck announced that its global Phase 3 TroFuse-015 trial of the investigational antibody-drug conjugate sacituzumab tirumotecan (sac-TMT, MK-2870) met its primary endpoint of overall survival in adults with third-line or later locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. Detailed results have not yet been released, and the drug is not approved for any use.
What happened
In its 20 November announcement, Merck, which sponsors the study, said that at the final analysis sac-TMT showed a statistically significant and clinically meaningful improvement in overall survival compared with treatment of physician’s choice. The company said the result was generally consistent across subgroups regardless of TROP2 expression status. Marjorie Green, senior vice president and head of oncology, global clinical development at Merck Research Laboratories, said in the release: “There is a tremendous unmet need for therapies that can improve survival for these patients.” Merck described sac-TMT as the first TROP2-directed antibody-drug conjugate to improve overall survival against physician’s choice treatment in a global Phase 3 study in this setting.
The secondary endpoint of progression-free survival, assessed by blinded independent central review, was not met. Objective response rate was nominally higher with sac-TMT, but Merck said it was not formally tested under the prespecified analysis plan. The company reported that safety was consistent with previously reported sac-TMT studies and that no new safety signals were seen. BioPharm International and CancerNetwork both reported the announcement on the same day and noted that the release gave no hazard ratio, median survival values or p-values.
Key details of the trial
| Item | Detail |
|---|---|
| Registry record | ClinicalTrials.gov NCT06356311 |
| Design | Phase 3, randomised, open-label, multicentre, global |
| Participants | 473 enrolled and randomised |
| Population | Third-line or later locally advanced unresectable or metastatic gastroesophageal adenocarcinoma |
| Comparator | Physician’s choice of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel |
| Primary endpoint | Overall survival, defined in the registry as time from randomisation to death from any cause |
| Secondary endpoints | Progression-free survival, objective response rate and duration of response (blinded independent central review), plus adverse-event measures |
| Sponsor | Merck Sharp and Dohme LLC; no collaborators listed |
| Dates and sites | Started 3 May 2024; primary completion 19 October 2026; 24 countries; now active, not recruiting |
According to CancerNetwork, eligible patients had measurable disease, progression after at least two prior lines of therapy and an ECOG performance status of 0 or 1, and TROP2 expression was not required for enrolment. Gastroesophageal adenocarcinoma, as Merck defines it, covers gastric, gastroesophageal junction and esophageal adenocarcinomas.
Background and context
Sac-TMT is a TROP2-directed antibody-drug conjugate with a belotecan-derived topoisomerase I inhibitor payload and a bifunctional linker, according to Merck. TROP2 is a protein that Merck says is overexpressed on tumour cells compared with healthy cells in many common cancers. Kelun-Biotech, a subsidiary of Kelun Pharmaceutical, developed the molecule, and under an exclusive licence and collaboration agreement Merck holds rights to develop, manufacture and commercialise it outside Greater China (Mainland China, Hong Kong, Macau and Taiwan).
TroFuse-015 is the second positive Phase 3 readout in Merck’s TroFuse programme, which Merck says includes 18 ongoing global Phase 3 trials across more than nine disease areas and more than 15,000 patients. The first was TroFuse-005 in pretreated endometrial cancer. CancerNetwork reported that median overall survival there was 19.0 months with sac-TMT versus 12.1 months with physician’s choice chemotherapy (hazard ratio 0.68; 95% confidence interval 0.55 to 0.84), and that the US Food and Drug Administration has accepted a biologics license application for that setting under priority review with a target action date of 15 June 2027.
Merck’s own estimates for 2026 put new US gastric cancer cases at about 31,500, with about 10,700 deaths, and new esophageal adenocarcinoma cases at more than 14,300.
Reaction
The announcement is a company topline release, and the trade press reported it as such. BioPharm International and CancerNetwork both repeated Merck’s statements on overall survival, progression-free survival and safety, and both noted that the release gave no figures for the size of the survival benefit. Merck itself cautioned in its forward-looking statement that there is no guarantee any pipeline candidate will receive approval or be commercially successful.
What it means for researchers, universities and research offices
For oncology researchers, the announcement is, in Merck’s description, the first overall survival result from a global Phase 3 study of a TROP2-directed antibody-drug conjugate in this setting, where the company says the need for survival-improving therapies is high. Interpretation has to wait for the full data: the hazard ratio, the median survival difference and the safety detail will determine how the result is read against the comparator drugs, and an open-label design means investigators will look closely at how endpoints were assessed. The missed progression-free survival endpoint will be part of that discussion.
For research offices and sites that took part, the trial is registered as ClinicalTrials.gov NCT06356311 and has passed its primary completion date, so the work now shifts to data lock, results reporting and publication. Teams that run similar studies can use this case as a reminder of why clinical trial registration of prespecified endpoints matters: the registry entry fixes overall survival as primary and progression-free survival as secondary, which is the frame within which Merck’s announcement is read. The trial’s design is documented in a clinical trial protocol, and the agent remains an investigational new drug until regulators decide otherwise.
The licensing arrangement is also relevant to technology-transfer offices: the molecule was developed by Kelun-Biotech in China and is being developed outside Greater China by Merck under an exclusive licence and collaboration agreement.
What happens next
Merck said the full results will be presented at an upcoming medical meeting, which it did not name, and will be shared with regulatory authorities. No regulatory submission for TroFuse-015 has been announced. In the wider programme, the sac-TMT application in endometrial cancer has an FDA action date of 15 June 2027, and Merck’s other Phase 3 TroFuse trials continue.
Sources
- Merck, announcement of TroFuse-015 topline results, 20 November 2026
- ClinicalTrials.gov, NCT06356311 study record
- BioPharm International, “Merck TROP2 ADC Meets Survival End Point in Gastroesophageal Cancer”, 20 November 2026
- CancerNetwork, “Sac-TMT Meets OS End Point in Pretreated Gastroesophageal Adenocarcinoma”, 20 November 2026







